- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00000963
A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine
A Randomized Comparative Trial of Two Doses of 2',3'-Dideoxyinosine (ddI) in Children With Symptomatic HIV Infection Who Are Either Unresponsive to Zidovudine and/or Who Are Intolerant to Zidovudine
To evaluate the effectiveness, safety, and tolerance of two doses of didanosine (ddI) in the treatment of children with symptomatic HIV disease who have had to discontinue zidovudine (AZT) because of intolerance and/or who have experienced progressive disease while on AZT.
The progression of immunodeficiency due to HIV infection can be delayed by using AZT. The benefits of AZT in adults with AIDS and severe AIDS-related complex (ARC) appear to last for approximately 12 to 18 months, at which time most patients have progressive deterioration. Recently published literature has described a reduced sensitivity of HIV isolated from patients after prolonged AZT treatment. Although the clinical significance of this is unclear, it makes the development of new antiretroviral drugs important.
Aperçu de l'étude
Description détaillée
The progression of immunodeficiency due to HIV infection can be delayed by using AZT. The benefits of AZT in adults with AIDS and severe AIDS-related complex (ARC) appear to last for approximately 12 to 18 months, at which time most patients have progressive deterioration. Recently published literature has described a reduced sensitivity of HIV isolated from patients after prolonged AZT treatment. Although the clinical significance of this is unclear, it makes the development of new antiretroviral drugs important.
Children who show AZT intolerance and/or progressive disease after 6 months of AZT therapy receive oral ddI at 1 of 2 doses for a minimum of 48 weeks, with a 48-week extension. Patients are seen for clinical and laboratory evaluations at scheduled times during the study. (Per 5/12/92 amendment, new patients will not be enrolled in the pharmacokinetics studies.) Per 10/31/94 amendment: Patients are eligible to receive blinded study drug for an additional 8-16 weeks after the final on-study visit, but no later than 2/15/95.
Type d'étude
Inscription
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Bayamon, Porto Rico, 00956
- Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds.
-
San Juan, Porto Rico
- Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
-
San Juan, Porto Rico, 00936
- San Juan City Hosp. PR NICHD CRS
-
-
-
-
California
-
Long Beach, California, États-Unis, 90801
- Long Beach Memorial Med. Ctr., Miller Children's Hosp.
-
Los Angeles, California, États-Unis, 90033
- Usc La Nichd Crs
-
Los Angeles, California, États-Unis
- UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS
-
Oakland, California, États-Unis, 94609
- Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab.
-
San Diego, California, États-Unis, 92093
- UCSD Maternal, Child, and Adolescent HIV CRS
-
San Francisco, California, États-Unis, 94143
- UCSF Pediatric AIDS CRS
-
Torrance, California, États-Unis
- Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases
-
-
Connecticut
-
Farmington, Connecticut, États-Unis, 06032
- Univ. of Connecticut Health Ctr., Dept. of Ped.
-
New Haven, Connecticut, États-Unis, 06504
- Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease
-
-
District of Columbia
-
Washington, District of Columbia, États-Unis, 20010
- Children's National Med. Ctr., ACTU
-
Washington, District of Columbia, États-Unis, 20060
- Howard Univ. Washington DC NICHD CRS
-
-
Florida
-
Miami, Florida, États-Unis, 33161
- Univ. of Miami Ped. Perinatal HIV/AIDS CRS
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30306
- Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Cook County Hosp.
-
Chicago, Illinois, États-Unis, 60614
- Chicago Children's CRS
-
Chicago, Illinois, États-Unis, 60637
- Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease
-
Chicago, Illinois, États-Unis, 60612
- Univ. of Illinois College of Medicine at Chicago, Dept. of Peds.
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis
- Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU
-
New Orleans, Louisiana, États-Unis
- Tulane/LSU Maternal/Child CRS
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology
-
Baltimore, Maryland, États-Unis, 21287
- Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- HMS - Children's Hosp. Boston, Div. of Infectious Diseases
-
Boston, Massachusetts, États-Unis, 02118
- BMC, Div. of Ped Infectious Diseases
-
Springfield, Massachusetts, États-Unis, 01199
- Baystate Health, Baystate Med. Ctr.
-
Worcester, Massachusetts, États-Unis, 01655
- WNE Maternal Pediatric Adolescent AIDS CRS
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Children's Hospital of Michigan NICHD CRS
-
-
New Jersey
-
New Brunswick, New Jersey, États-Unis
- UMDNJ - Robert Wood Johnson
-
Paterson, New Jersey, États-Unis
- St. Joseph's Hosp. & Med. Ctr. of New Jersey
-
-
New York
-
Albany, New York, États-Unis, 12208
- Children's Hospital at Albany Medical Center, Dept. of Peds.
-
Bronx, New York, États-Unis, 10457
- Bronx-Lebanon Hosp. IMPAACT CRS
-
Brooklyn, New York, États-Unis, 11203
- SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
-
Great Neck, New York, États-Unis, 11021
- North Shore-Long Island Jewish Health System, Dept. of Peds.
-
New Hyde Park, New York, États-Unis, 11040
- Schneider Children's Hosp., Div. of Infectious Diseases
-
New York, New York, États-Unis, 10032
- Columbia IMPAACT CRS
-
New York, New York, États-Unis, 10037
- Harlem Hosp. Ctr. NY NICHD CRS
-
New York, New York, États-Unis, 10016
- NYU Med. Ctr., Dept. of Medicine
-
New York, New York, États-Unis, 10032
- Incarnation Children's Ctr.
-
New York, New York, États-Unis, 10029
- Metropolitan Hosp. NICHD CRS
-
Rochester, New York, États-Unis, 14642
- Univ. of Rochester ACTG CRS
-
Stony Brook, New York, États-Unis, 11794
- SUNY Stony Brook NICHD CRS
-
Syracuse, New York, États-Unis, 13210
- SUNY Upstate Med. Univ., Dept. of Peds.
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- DUMC Ped. CRS
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Case CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- The Children's Hosp. of Philadelphia IMPAACT CRS
-
Philadelphia, Pennsylvania, États-Unis, 19134
- St. Christopher's Hosp. for Children
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Med. Univ. of South Carolina, Div. of Ped. Infectious Diseases
-
-
Texas
-
Dallas, Texas, États-Unis, 75235
- Children's Med. Ctr. Dallas
-
Houston, Texas, États-Unis, 77030
- Texas Children's Hosp. CRS
-
-
Washington
-
Seattle, Washington, États-Unis, 98105
- UW School of Medicine - CHRMC
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Prophylaxis treatment for Pneumocystis carinii pneumonia (PCP).
- Immunoglobulin.
- Maintenance therapy with amphotericin B (l mg/kg) up to 5 days/week.
Concurrent Treatment:
Allowed:
- Blood transfusions.
Prior Medication:
Allowed:
- Prophylaxis treatment for Pneumocystis carinii pneumonia (PCP).
Patients enrolled in ACTG 128 and ACTG 138 must meet study end points or meet protocol definitions for being permanently off zidovudine (AZT) before enrolling in this study.
- Patients currently enrolled in ACTG 051 who have not reached the study end points but who meet the entry criteria for ACTG 144 may be co-enrolled in ACTG 144.
- Patient or guardian available to give written informed consent.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded.
- Hypersensitivity to didanosine (ddI).
- Symptomatic cardiomyopathy.
- Seizures that are not well controlled by ongoing anticonvulsant therapy.
- Symptomatic pancreatitis.
- Grade 1 or higher peripheral neuropathy.
- Active malignancy requiring chemotherapy.
Concurrent Medication:
Excluded:
- Zidovudine (AZT), other antiretroviral agents, biological modifiers, and investigational medications.
Avoid:
- Drugs with potential to cause peripheral neuropathy or pancreatitis.
Patients with the following are excluded:
- Active malignancy requiring concomitant chemotherapy.
Prior Medication:
Excluded:
- Antiretroviral agents other than zidovudine (AZT) or dideoxycytidine (ddC) within 4 weeks of study entry.
- Immunomodulating agents such as interferons, isoprinosine, or interleukin-2 within 2 weeks of entry.
- Any other experimental therapy within 1 week of entry.
- Drugs that have or will cause prolonged neutropenia, significant pancreatitis, significant nephrotoxicity, or peripheral neuropathy within 1 week of entry.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chaise d'étude: Frenkel LM
- Chaise d'étude: Bryson Y
- Chaise d'étude: Stiehm R
Publications et liens utiles
Publications générales
- Perrier M, Schwarz T, Gonzalez O, Brounts S. Squamous cell carcinoma invading the right temporomandibular joint in a Belgian mare. Can Vet J. 2010 Aug;51(8):885-7.
- Carey VJ, Yong F, Frenkel L, McKinney R. Enhancing the prognostic value of bodily growth histories in HIV-positive pediatric cohorts. Int Conf AIDS. 1996 Jul 7-12;11(2):134 (abstract no WeC3444)
Dates d'enregistrement des études
Dates principales de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections par virus à ARN
- Maladies virales
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections à lentivirus
- Infections à rétroviridae
- Syndromes d'immunodéficience
- Maladies du système immunitaire
- Maladies à virus lents
- Infections à VIH
- Infections
- Syndrome immunodéficitaire acquis
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Agents antiviraux
- Inhibiteurs de la transcriptase inverse
- Inhibiteurs de la synthèse des acides nucléiques
- Inhibiteurs d'enzymes
- Agents anti-VIH
- Agents antirétroviraux
- Antimétabolites
- Didanosine
Autres numéros d'identification d'étude
- ACTG 144
- 11119 (DAIDS ES Registry Number)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Infections à VIH
-
Icahn School of Medicine at Mount SinaiIRRASRecrutementHémorragie intraventriculaire (HIV)États-Unis
-
Yale UniversityComplétéPrématurité | Nourrissons de très faible poids à la naissance | Hémorragie intraventriculaire (HIV) | Saignement dans le cerveauÉtats-Unis
-
West Virginia UniversityInscription sur invitationInfection de la peau et des tissus mous | Infection gastro-intestinale | Infection pulmonaire | Infection des os et des articulations | Infection endovasculaire | Infection génito-urinaireÉtats-Unis
-
Taipei Medical University WanFang HospitalInconnue
-
Croydon Health Services NHS TrustComplétéInfection du site opératoire | Infection de la plaie | Césarienne; Infection | Infection périnéaleRoyaume-Uni
-
Ondine Biomedical Inc.ComplétéInfection du site opératoire | Infection nosocomiale | Infection associée aux soins de santéÉtats-Unis
-
Angela BiancoStryker NordicRésiliéCésarienne | Infection du site opératoire | Infection nosocomialeÉtats-Unis
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... et autres collaborateursRecrutementInfection prothétique-articulaire | Infection de la hanche | Infection; Genou, ArticulationPays-Bas
-
Cairo UniversityRecrutementInfection postopératoire | Complications de la césarienne | Infection vaginaleEgypte
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemComplétéInfection du site opératoire | Infection superficielle du site opératoire | Infection profonde du site chirurgical | Infection du site chirurgical d'un organe/de l'espaceÉtats-Unis